Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Pre-Tax Income : ¥1,152 Mil (TTM As of Dec. 2024)

Tibet Rhodiola Pharmaceutical Holding Co Pre-Tax Income Chart

Tibet Rhodiola Pharmaceutical Holding Co Annual Data
	Trend	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
Pre-Tax Income		Get a 7-Day Free Trial					470.32	254.85	463.39	898.20	1,152.08

Tibet Rhodiola Pharmaceutical Holding Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Pre-Tax Income	Get a 7-Day Free Trial															-56.48	347.44	348.43	186.95	269.26

Competitive Comparison of Tibet Rhodiola Pharmaceutical Holding Co's Pre-Tax Income

For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Rhodiola Pharmaceutical Holding Co's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tibet Rhodiola Pharmaceutical Holding Co's Pre-Tax Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tibet Rhodiola Pharmaceutical Holding Co's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Tibet Rhodiola Pharmaceutical Holding Co's Pre-Tax Income falls into.

Tibet Rhodiola Pharmaceutical Holding Co Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Tibet Rhodiola Pharmaceutical Holding Co's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Tibet Rhodiola Pharmaceutical Holding Co's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,152 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tibet Rhodiola Pharmaceutical Holding Co  (SHSE:600211) Pre-Tax Income Explanation

Tibet Rhodiola Pharmaceutical Holding Co's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

During the past 13 years, Tibet Rhodiola Pharmaceutical Holding Co's highest Pretax Margin was 41.05%. The lowest was 7.69%. And the median was 27.98%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tibet Rhodiola Pharmaceutical Holding Co Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Tibet Rhodiola Pharmaceutical Holding Co's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Tibet Rhodiola Pharmaceutical Holding Co Business Description